Maria Pia Prudenzano - Centro Cefalee, Clinica Neurologica “L. Amaducci”. Dipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso. Università di Bari
Migraine affects about 12% of individuals in the general population. Although it may occur at all ages, its prevalence is lower in children and the elderly, reaching a peak in the 25- to 39-year-old age range that corresponds to that of maximum productivity (1). After menarche, there is a much higher prevalence in women than in men.
Global Burden of Diseases places migraine among the ten most disabling neurological pathologies in the world population and in first place as a cause of disability below the age of 50 (2).
The social impact of this pathology is high both in terms of direct costs, due to diagnostic investigations and treatment, and indirect costs, which are far more burdensome and derive from the loss of work days and productivity (3).
The psychopathological aspects of migraine have long been a research topic of great interest. In the 1950s, Wolff identified a distinctive personality pattern and described the migraine patient, especially if a woman, as a subject prone to perfectionism and neuroticism (4).
In more recent times, results of numerous epidemiological studies, among which the studies of Breslau and Merikangas represent true milestones, show that migraineurs have a 2 to 4 times greater risk of depression than non-migraineurs (5,6,7).
The association between depression and migraine appears stronger in the form with aura than that without aura. In patients with migraine-associated depression, the symptoms of the migraine attack, including osmophobia and allodynia, are positively correlated with the severity of depressive symptoms. Moreover, those suffering from depression seem to be more inclined not to respond to anti-migraine treatments and suffer from abuse of symptomatic drugs (5,6,7).
Longitudinal observations have provided some evidence to support the existence of a bidirectional pathogenetic relationship between migraine and depression (5,6,7).
The risk of suffering from bipolar disorder is about twice as high in migraine patients as compared to non-migraineurs. Conversely, in patients with bipolar disorder, migraine is related to some negative prognostic factors such as early onset, more rapid cycles and more severe and more frequent depressive episodes (8).
In the migraine population, anxiety disorders are even more common than depressive disorders, including generalized anxiety, obsessive-compulsive disorder, and panic disorder.
A possible bidirectional causal relationship with migraine has also been hypothesised for anxiety. Studies on the polymorphism of the serotonin transporter gene have shown in both conditions a higher frequency of the allele s, suggesting the possibility of a common genetic basis (5,6,7).
Post-traumatic stress disorder, sometimes related to a personal history of abuse or neglect, also appears to be particularly frequent in patients with migraines (5,6,7).
It has been shown that the degree of disability, and the direct and indirect costs of migraine increase with the frequency of attacks and in relation to psychiatric comorbidity (9).
Psychiatric comorbidity is also considered among the risk factors of chronic migraine, which can be modified, if the psychiatric disorder is diagnosed and treated appropriately (5,6,7).
The frequency with which migraine is associated with psychiatric symptoms and disorders is so high that it is unlikely that their connection is causal. To explain this association numerous theories have been advanced that call into question a possible common neurotransmission, serotoninergic or dopaminergic dysfunction. An important role could be played by stress (also caused by the repetition of attacks) and by the consequent hyperactivity of the hypothalamus-pituitary-adrenal system (6).
Neuroimaging studies show in the migraine patient the presence of functional or structural alterations in the brain areas involved in the emotional response to pain such as the anterior cingulate cortex, the insula, the prefrontal cortex, the hippocampus and the amygdala (6). These alterations have been interpreted as an expression of an abnormal affective-motivational process of nociceptive stimuli that includes emotional reactions to pain, light, noise and odors (6). In confirmation of this interpretation, it has been found that migraineurs show a greater activation of these areas in response to a painful stimulus compared to non-migraineurs and that, in conditions of rest, are characterized by a stronger connectivity between affective-motivational areas and those responsible for discriminating sensory stimuli. Similar aspects have also been found in patients with depression and other psychiatric disorders, suggesting that they may in some way represent a common pathogenetic link (6). The analysis of genetic study data conducted on large case studies indicates that at least in a subgroup of subjects, migraine may be a symptom or a consequence of depression (6).
However, according to the experts who have drafted the current international classification of headaches, the scientific evidence available so far is not sufficient to demonstrate with certainty the existence of a causal relationship between depressive disorders, anxiety disorders or related disorders to stress/trauma and migraine or other forms of headache, therefore the headaches attributed to these psychiatric disorders respectively are not recognized as nosological entities to be used in clinical diagnosis, but are listed in the appendix with the indication to use them only for research purposes (10) . There are only two exceptions: headache attributed to somatoform disorder and headache attributed to psychotic disorder (10).
From the clinical point of view, in migraineurs, comorbidity with symptoms or psychiatric disorders must always be sought and the diagnosis can be facilitated by semi-structured interviews and ad hoc questionnaires.
There are few studies on the effects of anti-migraine therapies on psychiatric comorbidity and although no final conclusions can be made so far on this aspect, some evidence on small patient samples shows that early and specific treatment of the migraine attack leads to an improvement in depressive symptoms detected with specific scales. Similarly, preventive therapy with botulinum toxin in migraineurs with anxiety and depression seems to induce, in parallel to the control of migraine, also an improvement of the psychiatric pathology, detected through the reduction of the scores reported in specific scales [eg. Beck Depression Inventory, Generalized Anxiety Disorder Assessment (7) (6)].
In some cases psychiatric consultation is important both to define the diagnosis and to coordinate the therapeutic interventions.
In the choice of the therapeutic program it is necessary to avoid drugs recognized as effective in anti-migraine prophylaxis but able to worsen the concomitant disorder (eg. topiramate in case of migraine and depression).
Drugs, possibly in monotherapy and in low doses, that are able to control both disorders (eg. propranolol in cases of mild anxiety) should be preferred.
The association with non-pharmacological treatments (progressive muscle relaxation, biofeedback, cognitive-behavioral techniques) can have synergistic therapeutic effects with longer lasting benefits and without side effects (6).
In this category of patients it is important to evaluate the presence of overweight and plan an appropriate diet (eg. ketogenic diet) associated with behavioral standards that will integrate the remaining therapy by also counteracting the potential undesirable effects on weight caused by certain drugs (eg. amitriptyline, flunarizine, etc.).
In conclusion, from the epidemiological, socio-economic and clinical point of view, the problem of comorbidity between migraine and psychiatric disorders appears to be significant, but further studies are needed to establish its nature with certainty.
Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018 Jun;8(6)
Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17
Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012). The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703-711
Davis RE, Smitherman TA, Baskin SM. Personality traits, personality disorders,and migraine: a review. Neurol Sci. 2013 May;34 Suppl 1:S7-10
Seng EK, Seng CD. Understanding migraine and psychiatric comorbidity. Curr Opin Neurol. 2016 Jun;29(3):309-13
Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):741-9
Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013 Aug;260(8):1960-9
Gordon-Smith K, Forty L, Chan C, et al. Rapid cycling as a feature of bipolar disorder and comorbid migraine. J Affect Dis 2015; 175:320–324
Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF,Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P. Cost of healthcare for patients with migraine in five European countries:results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012 Jul;13(5):361-78
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211
Winner of the Greppi Award 2018: Delphine Magis “Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials” More information: https://t.co/82QkAVPApm